Introduction and Objective: Insulin resistance occurs at lower BMI in Asian Americans, but metabolic differences, particularly between Asian American ethnic subgroups, are not well-characterized in the type 1 diabetes (T1D) population. We compared metabolic markers and incretin-agonist prescription rates in Asian vs non-Asian people with T1D (PwT1D), and across Asian subgroups. Methods: PwT1D were identified using an EHR-based classification algorithm adapted from Klompas et al. (2013) from Dec 2017-Nov 2025. We collected general demographic information, metabolic markers including HbA1c, Triglyceride:HDL (TG:HDL), and AST:ALT ratios, and the prevalence of semaglutide/tirzepatide prescriptions amongst different groups of PwT1D. Continuous variables were compared using independent two-sample t tests (two groups) and one-way analysis of variance (ANOVA; 2 groups), and categorical variables were compared using chi-square tests. Results: 2161 T1D individuals were identified, 460 individuals (21.3%) identified as Asian. Ethnic sub-classification was available for 155 individuals (33.7%) of the Asian T1D cohort. Differences between groups are summarized in Table 1. Conclusion: We were able to detect differences in BMI between Asians, Non-Asians, and also between major Asian subgroups. HbA1c also varied between the Asian and non-Asian cohort. More data is needed to elucidate differences in insulin resistance for PwT1D among Asian and Non-Asian groups. Disclosure Y. Liu: None. R.S. Kingman: None. B. Suh: None. K. Kingston: None. M. Morgan: None. M. Basina: None. R. Lal: Consultant; Current; Abbott Diabetes, Adaptyx Biosciences. Consultant; Ended; Biolinq, Capillary Biomedical, Deep Valley Labs. Consultant; Current; Gluroo, Portal Diabetes, Tidepool. Advisory Panel; Ended; ProventionBio, Lilly, Sanofi, Rezolute. Funding Center for Asian Health Research and Education at Stanford
Liu et al. (Fri,) studied this question.